头孢唑林钠(Cefazolin Sodium) - 药物靶点：PBPs_在研适应症：胆管感染，骨和关节感染，心内膜炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CEZ、Cefazo1in Sodium、Cefazolin

+ [24]

靶点

PBPs

作用方式

抑制剂

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Hikma Pharmaceuticals USA, Inc.Baxter Healthcare Corp.

B. Braun Medical, Inc.

+ [3]

非在研机构

GSK Plc

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1973-10-04),

革兰氏阴性菌感染

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H14N8NaO4S3

InChIKeyBXZNAOVMWGRSJT-WYUVZMMLSA-N

CAS号27164-46-1

查看全部结构式(3)

关联

153

项与头孢唑林钠相关的临床试验

NCT06567808

/ Not yet recruiting临床4期

Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial

The goal of this pragmatic, multi-centre factorial cluster randomized cross-over trial is to assess the efficacy of a combination of cefazolin plus vancomycin compared to cefazolin monotherapy, as well as a comparison of short versus long-term prophylaxis with four study arms: 1) cefazolin short-term, 2) cefazolin long-term, 3) cefazolin plus vancomycin short-term and 4) cefazolin plus vancomycin long-term.

开始日期2025-05-01

申办/合作机构

Hamilton Health Sciences Corporation

[+1]

NCT06920147

/ Not yet recruiting临床4期IIT

PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network

The purpose of this study is to compare the effectiveness of 2 prophylactic antibiotic regimens, ertapenem and cefazolin with metronidazole, in preventing organ space surgical site infections (OS-SSI) after emergency trauma laparotomy embedded into routine clinical care and to validate a Bayesian OS-SSI risk calculator using Trauma Quality Improvement Program (TQIP) standardized variables

开始日期2025-05-01

申办/合作机构

University of Texas Health Science Center at Houston

NCT06406114

/ Not yet recruiting临床2期IIT

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

开始日期2025-04-15

申办/合作机构

The General Hospital Corp.

[+1]

100 项与头孢唑林钠相关的临床结果

登录后查看更多信息

100 项与头孢唑林钠相关的转化医学

登录后查看更多信息

100 项与头孢唑林钠相关的专利（医药）

登录后查看更多信息

18,728

项与头孢唑林钠相关的文献（医药）

2025-07-01·The American Journal of Emergency Medicine

Cephalexin twice daily versus four times daily for the treatment of urinary tract infections diagnosed in the emergency department

Article

作者: Hamby, Aaron ; Morrisette, Taylor ; Rath, Abigail ; Billups, Kelsey ; Burgoon, Rachel

BACKGROUNDCephalexin is an oral cephalosporin approved for the treatment of urinary tract infections (UTIs). Data regarding the optimal dosing interval for cephalexin in UTIs, including uncomplicated UTIs (uUTI) and complicated UTIs (cUTI), remains limited.OBJECTIVEThe primary objective of this study was to compare the rates of treatment failure between patients prescribed cephalexin twice daily versus four times daily for the management of uUTIs and cUTIs once discharged from the emergency department (ED).METHODSThis retrospective, single-center cohort study conducted between July 31st, 2016 and July 31st, 2023, included patients who were ≥ 18 years of age, discharged from the ED with a diagnosis of UTI, prescribed cephalexin 500 mg twice or four time daily, and a urine culture positive for Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis susceptible to cefazolin. Treatment failure was defined as return to the ED or outpatient clinic with similar or worsening UTI symptoms or change in antibiotic therapy within 30 days of the initial ED visit. Sub-group analyses were performed for both uUTI and cUTIs.RESULTSIn total, 214 patients were included in this analysis (50.0 % in each group). Treatment failure rates between the twice daily and four times daily dosing groups were 18.7 % versus 15.0 % (P = 0.465). Treatment failure rates in those with uUTI were 14.9 % versus 8.1 % (P = 0.197) and those with cUTI were 27.3 % versus 30.3 % (P = 0.786).CONCLUSIONFor patients with UTIs, there was no statistically significant difference in treatment failure rates between patients prescribed cephalexin twice daily versus four times daily. These findings suggest cephalexin dosed twice daily may be a reasonable option for the outpatient management of UTIs diagnosed in the ED, thus increasing adherence and decreasing cost without statistically compromising effectiveness.

2025-07-01·Microbial Pathogenesis

Distinct temporal profiles of AMPs and cytokines in pleural fluids from open and closed thoracic surgeries and exploration of synergy with antibiotics and wound healing effects

Article

作者: Ghorbanizamani, Faezeh ; Memmedov, Rza ; Timur, Suna ; Moulahoum, Hichem ; Zihnioglu, Figen ; Aksu, Didem ; Akcam, Tevfik Ilker ; Tok, Kerem ; Gürsoy, Dilara ; Turhan, Kutsal

Antimicrobial peptides (AMPs) play a crucial role in immune defense and wound healing. Their expression and function in pleural fluids following different thoracic surgeries remain underexplored. This study aims to compare AMP and cytokine profiles in pleural fluids from patients undergoing open and closed thoracic surgeries and assess their antimicrobial efficacy and wound healing potential. Pleural fluid and blood samples were collected from 24 patients at multiple time points post-surgery. Levels of four AMPs (DEF-1β, Angiogenin, RNase7, LL-37) and five cytokines (IL-1β, IL-2, IL-6, IL-8, TNF-α) were measured. Antimicrobial activity against E. coli and S. aureus was tested, including combinations with cefazolin. Wound healing was assessed using an in vitro scratch assay. DEF-1β was significantly higher in open surgeries, while Angiogenin was elevated in closed surgeries. Pleural fluids exhibited strong antimicrobial activity, enhanced when combined with cefazolin. Wound healing was rapid but transient with open surgery fluids and more sustained with closed surgery fluids. The distinct AMP profiles and synergistic effects with antibiotics suggest that pleural fluid-derived AMPs could enhance postoperative care. Further studies are needed to explore their therapeutic potential.

2025-07-01·Diagnostic Microbiology and Infectious Disease

A case of pyogenic vertebral osteomyelitis and psoas abscess caused by Haemophilus influenzae: Diagnostic value of 16S ribosomal RNA gene analysis in a culture-negative case

Article

作者: Oshiro, Yusuke ; Ohkusu, Kiyofumi ; Ishiki, Haruka ; Toma, Kenya ; Shinzato, Takashi

Haemophilus influenzae is a rare cause of pyogenic osteomyelitis, with only eleven reported adult cases. We present a case of H. influenzae vertebral osteomyelitis and psoas abscess in a 48-year-old woman who had received prior antibiotic therapy before the event. She subsequently developed worsening lower back pain, and magnetic resonance imaging revealed L4/L5 osteomyelitis with psoas abscess. Despite empiric cefazolin therapy, her condition deteriorated. All microbiological cultures remained negative, including blood and aspirated pus from the lesion. Broad-range 16S ribosomal RNA gene polymerase chain reaction and sequencing analysis identified β-lactamase-negative ampicillin-susceptible H. influenzae as the causative pathogen. After switching to cefotaxime, the patient improved and completed treatment with oral levofloxacin without recurrence. This case demonstrates the value of molecular techniques in diagnosing culture-negative infections, particularly in antibiotic-pretreated patients.

107

项与头孢唑林钠相关的新闻（医药）

2025-04-10

·Pharmaceutical Technology

FDA approves injectable antibiotics for B Braun drug delivery system

B Braun’s Duplex system is engineered to minimise the risk of contamination and medication errors. Credit: Bendix M/Shutterstock. The US Food and Drug Administration (FDA) has approved the injectable antibiotics Piperacillin and Tazobactam for use in B Braun Medical’s Duplex drug delivery system. The drug delivery system is a ready-to-activate container that separates pre-measured medication and diluent until activation by the provider during treatment. The system decreases process time by around four minutes for each dose and saves considerable labour time in comparison to the Baxter Mini-Bag Plus container system and traditional compounding methods. B Braun’s Duplex system is engineered to minimise risks of contamination and medication errors. Its closed-system design protects the potency of the drug and ensures that the diluent cannot be administered without the medication. With fewer process steps, the system has been shown to decrease the possibility of medication errors by 54% versus traditional compounding. The system eliminates the need for thawing and is suitable for storage at room temperature or in automated dispensing cabinets. B Braun medical marketing senior director Jeremy Greene stated: “We are excited to introduce Piperacillin and Tazobactam in our innovative Duplex drug delivery system, designed to save time, labour and space, and reduce waste. “Enhancing efficiency for nurses and pharmacists aligns with our commitment to providers and the patients they serve.” This is B Braun’s second introduction of antibiotics into the drug delivery system in 2025, following the launch of Cefazolin 3g, and is part of the company’s strategy to expand its portfolio of injectable drugs in the US. Headquartered in Pennsylvania, the company specialises in pharmacy products and infusion therapy.

合格传染病产品

2025-04-07

·信狐药迅

东阳光英强布韦片掘金7.8亿市场；青峰创新流感药玛舒拉沙韦获批上市| 新获批(3.31-4.6）

每周药品注册获批数据，分门别类呈现，一目了然。(3.31-4.6）新药上市申请药品名称企业注册分类受理号SHR0302片江苏恒瑞医药股份有限公司1CXHS2300108GP681片江西青峰药业有限公司1CXHS2300106英强布韦片宜昌东阳光长江药业股份有限公司1CXHS2300069新药临床申请药品名称企业注册分类受理号INS018_055片英矽智能科技(上海)有限公司1CXHL2500120HRS-1167片江苏恒瑞医药股份有限公司1CXHL2500111HRS-1167片江苏恒瑞医药股份有限公司1CXHL2500110HRS-1167片江苏恒瑞医药股份有限公司1CXHL2500109BIOS-0618片杭州百诚医药科技股份有限公司1CXHL2500104BIOS-0618片杭州百诚医药科技股份有限公司1CXHL2500103TQB3912片正大天晴药业集团股份有限公司1CXHL2500108TQB3912片正大天晴药业集团股份有限公司1CXHL2500107HBW-012336胶囊成都海博为药业有限公司1CXHL2500099HRS-6719片山东盛迪医药有限公司1CXHL2500094HRS-6719片山东盛迪医药有限公司1CXHL2500092GenSci128片长春金赛药业有限责任公司1CXHL2500080IMP1707片上海瑛派药业有限公司1CXHL2500088GenSci128片长春金赛药业有限责任公司1CXHL2500081IMP1707片上海瑛派药业有限公司1CXHL2500089HS-10380片江苏豪森药业集团有限公司1CXHL2401508CMC-2310口溶膜复星医药(徐州)有限公司2.2CXHL2500113CMC-2310口溶膜复星医药(徐州)有限公司2.2CXHL2500112ASKC635干混悬剂江苏奥赛康药业有限公司2.2CXHL2500083HZ039干混悬剂浙江和泽医药科技股份有限公司2.2CXHL2500029HZ039干混悬剂浙江和泽医药科技股份有限公司2.2CXHL2500028注射用多西他赛(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2500118HK241雾化吸入溶液南京华盖制药有限公司2.4CXHL2500106三价流感病毒裂解疫苗(ZFA02佐剂)安徽智飞龙科马生物制药有限公司1.3CXSL2500007PT217凡恩世制药(北京)有限公司1CXSL2500090注射用DR30206浙江道尔生物科技有限公司1CXSL2500079BNT324映恩生物制药(苏州)有限公司1CXSL2500073BNT327百欧恩泰(上海)医药有限公司1CXSL2500072注射用TQB2922正大天晴药业集团南京顺欣制药有限公司1CXSL2500062注射用7MW3711迈威(上海)生物科技股份有限公司1CXSL2500057注射用ZL-1310再鼎医药(上海)有限公司1CXSL2500052SSGJ-627注射液三生国健药业(上海)股份有限公司1CXSL2500024ZT006片北京质肽生物医药科技有限公司1CXSL2500021ZT006片北京质肽生物医药科技有限公司1CXSL2500020ZT006片北京质肽生物医药科技有限公司1CXSL2500019泰它西普注射液荣昌生物制药(烟台)股份有限公司2.1;2.2CXSL2500014DJ-01注射剂苏州德进生物制药有限公司2.4CXSL2500059仿制药申请药品名称企业注册分类受理号腺苷钴胺胶囊四川新斯顿制药股份有限公司3CYHS2302959吡拉西坦注射液石家庄凯达生物工程有限公司3CYHS2302936吡拉西坦注射液石家庄凯达生物工程有限公司3CYHS2302935吡拉西坦注射液石家庄凯达生物工程有限公司3CYHS2302934氨茶碱注射液浙江北生药业汉生制药有限公司3CYHS2302798碳酸氢钠林格注射液河北天成药业股份有限公司3CYHS2302620甲硫酸新斯的明注射液上海旭东海普药业有限公司3CYHS2302585甲硫酸新斯的明注射液上海旭东海普药业有限公司3CYHS2302584奥美拉唑碳酸氢钠胶囊(II)宁波美诺华天康药业有限公司3CYHS2302576奥美拉唑碳酸氢钠胶囊宁波美诺华天康药业有限公司3CYHS2302575盐酸多巴胺注射液遂成药业股份有限公司3CYHS2302519盐酸多巴胺注射液遂成药业股份有限公司3CYHS2302518依帕司他片河北瑞森药业有限公司3CYHS2302427布美他尼注射液四川美大康华康药业有限公司3CYHS2302402重酒石酸间羟胺注射液安徽美来药业股份有限公司3CYHS2302378脑脊髓手术用灌流液山东齐都药业有限公司3CYHS2302269氯化钾注射液南京赛瑞谱顿制药有限公司3CYHS2302235碳酸氢钠注射液石家庄四药有限公司3CYHS2302249福多司坦口服溶液江苏联环药业股份有限公司3CYHS2302224氯化钾注射液海南景泽康生物科技有限公司3CYHS2302201硫辛酸片湖南先施制药有限公司3CYHS2302036硫辛酸片湖南先施制药有限公司3CYHS2302035泊马度胺胶囊扬子江药业集团有限公司3CYHS2301871泊马度胺胶囊扬子江药业集团有限公司3CYHS2301870米诺地尔搽剂山东百诺医药股份有限公司3CYHS2301792左乙拉西坦缓释片东北制药集团沈阳第一制药有限公司3CYHS2301768己酮可可碱注射液河南朗冠药品制剂研究院有限公司3CYHS2301750盐酸艾司洛尔注射液海南倍特药业有限公司3CYHS2301678西格列汀二甲双胍缓释片齐鲁制药(海南)有限公司3CYHS2301590羧甲司坦口服溶液北京沃邦医药科技有限公司3CYHS2301440聚乙二醇3350散哈尔滨葵花药业有限公司3CYHS2301409米诺地尔搽剂北京博喆研医药科技有限公司3CYHS2301232二羟丙茶碱注射液安徽金太阳生化药业有限公司3CYHS2301131福多司坦口服溶液四川益生智同医药生物科技发展有限公司3CYHS2301118盐酸阿比多尔片石家庄四药有限公司3CYHS2201031国;CYHS2201031酒石酸溴莫尼定滴眼液石家庄格瑞药业有限公司4CYHS2400266硫酸氨基葡萄糖胶囊广州迈凯安生物医药研究院有限公司4CYHS2400149美阿沙坦钾片江苏联环药业股份有限公司4CYHS2303603美阿沙坦钾片江苏联环药业股份有限公司4CYHS2303602帕利哌酮缓释片合肥立方制药股份有限公司4CYHS2303619帕利哌酮缓释片合肥立方制药股份有限公司4CYHS2303618盐酸尼卡地平注射液石家庄四药有限公司4CYHS2303526甲钴胺片湖南千金湘江药业股份有限公司4CYHS2303515利培酮片重庆药友制药有限责任公司4CYHS2303313利培酮片重庆药友制药有限责任公司4CYHS2303312玻璃酸钠滴眼液苏州工业园区天龙制药有限公司4CYHS2303281富马酸丙酚替诺福韦片河北山姆士药业有限公司4CYHS2303238碘海醇注射液浙江兄弟药业有限公司4CYHS2303204碘海醇注射液浙江兄弟药业有限公司4CYHS2303203碘海醇注射液浙江兄弟药业有限公司4CYHS2303202盐酸决奈达隆片山东新时代药业有限公司4CYHS2303144西罗莫司凝胶福建科瑞药业有限公司4CYHS2303061艾地骨化醇软胶囊正大制药(青岛)有限公司4CYHS2303058艾地骨化醇软胶囊正大制药(青岛)有限公司4CYHS2303057维生素B12滴眼液广州仁恒医药科技股份有限公司4CYHS2302984盐酸贝尼地平片浙江高跖医药科技股份有限公司4CYHS2302979盐酸贝尼地平片浙江高跖医药科技股份有限公司4CYHS2302978盐酸普拉克索缓释片植恩生物技术股份有限公司4CYHS2302880盐酸普拉克索缓释片植恩生物技术股份有限公司4CYHS2302878非诺贝特酸胆碱缓释胶囊江苏慧聚药业股份有限公司4CYHS2302853非诺贝特酸胆碱缓释胶囊江苏慧聚药业股份有限公司4CYHS2302852奥氮平片重庆药友制药有限责任公司4CYHS2302838奥氮平片重庆药友制药有限责任公司4CYHS2302837熊去氧胆酸胶囊杭州民生药业股份有限公司4CYHS2302808布洛芬混悬滴剂哈尔滨葵花药业有限公司4CYHS2302694他达拉非片河北瑞森药业有限公司4CYHS2302219吸入用乙酰半胱氨酸溶液广州世济医药科技有限公司4CYHS2302167瑞戈非尼片北京双鹭药业股份有限公司4CYHS2301372奥利司他胶囊安徽省先锋制药有限公司4CYHS2300819奥利司他胶囊安徽省先锋制药有限公司4CYHS2300818注射用硼替佐米广东鼎信医药科技有限公司4CYHS2201206酮洛芬贴剂河北一品制药股份有限公司3CYHL2500023洛索洛芬钠凝胶贴膏云南白药集团无锡药业有限公司4CYHL2500024冻干人用狂犬病疫苗(人二倍体细胞)北京科兴中维生物技术有限公司3.3CXSL2500017静注人免疫球蛋白(10%)广东双林生物制药有限公司3.2CXSL2500022进口申请药品名称企业注册分类受理号他氟噻吗滴眼液Santen Oy5.1JXHS2300015纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400059纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400058伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400056伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400055阿柏西普眼内注射溶液Bayer AG3.1JXSS2300092罗泽利昔珠单抗注射液UCB, Inc.3.1JXSS2300081奥瑞利珠单抗注射液Roche Pharma (Schweiz) AG3.1JXSS2300065奥瑞利珠单抗注射液Roche Pharma (Schweiz) AG3.1JXSS2300064注射用头孢唑林钠Taiwan Biotech Co., Ltd.5.2JYHS2300132注射用头孢唑林钠Taiwan Biotech Co., Ltd.5.2JYHS2300131氟维司群注射液EVER Valinject GmbH5.2JYHS2200093利鲁唑片Kenton Chemicals and Pharmaceuticals Corporation5.2JYHS2200063国;JYHS2200063TAK-279胶囊Takeda Development Center Americas, Inc.1JXHL2500005TAK-279胶囊Takeda Development Center Americas, Inc.1JXHL2500004AZD5492AstraZeneca AB1JXSL2500016AZD5492AstraZeneca AB1JXSL2500015AZD2936AstraZeneca AB1JXSL2500014HCB301注射液FBD Biologics Limited1JXSL2500010VG901注射液ViGeneron GmbH1JXSL2500003本瑞利珠单抗注射液AstraZeneca AB2.2JXSL2500019度伐利尤单抗注射液MedImmune LLC2.2JXSL2500017Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500013Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500012艾加莫德α注射液argenx BV3.1JXSL2500011中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗上市批准申请上市

2025-03-30

·药融圈

狂揽58亿，净利飙升27.6%！国邦医药靠什么领跑原料药赛道？

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2024年，在全球经济波动与行业竞争加剧的背景下，国邦医药交出了一份亮眼的成绩单。公司全年实现营业收入58.91亿元，同比增长10.12%；归母净利润7.82亿元，同比大幅增长27.61%，净利润增速远超营收，展现出强劲的盈利能力和成本控制水平。作为一家覆盖医药原料药、动保产品的全球化企业，国邦医药通过深化“多品种头部企业”战略，持续巩固行业地位，并加速向高质量发展迈进。业绩亮点：核心业务双轮驱动，毛利率结构性优化1.医药板块：优势产品持续发力医药板块贡献收入38.22亿元（占比65%），同比增长9.65%，毛利率提升3.55个百分点至28.82%。核心产品包括阿奇霉素、克拉霉素等大环内酯类抗生素原料药，以及心血管、抗肿瘤类原料药。其中，头孢系列产品产销强劲增长，特色原料药销售额同比提升超30%，新获批布南色林、马普腾坦等原料药进一步丰富了产品矩阵。2.动保板块：产能释放带动规模扩张动保板块收入20.17亿元（占比34%），同比增长9.94%。氟苯尼考年销量突破3000吨，盐酸多西环素产销两旺，市场占有率稳步提升。尽管动保原料药毛利率因行业竞争微降1.81个百分点至18.86%，但产能利用率逐季提升，规模效应逐步显现。3.盈利质量改善公司通过优化生产工艺、降低中间体自给成本，推动医药原料药毛利率提升6.68个百分点。此外，经营性现金流净额同比增长36.7%至7.06亿元，现金流管理能力显著增强。产能布局：两大基地支撑全球供应，绿色生产筑牢竞争力国邦医药在浙江上虞、山东潍坊两大国家级工业园区布局现代化生产基地，总占地面积超2500亩，形成规模化、集约化制造优势：医药板块：38个原料药国内获批，15个产品获欧盟CEP认证，头孢唑林钠等新品投产；动保板块：16个动保原料药国内获批，氟苯尼考通过美国FDA认证，覆盖欧洲30余国市场；环保投入：全年安全环保投入1.23亿元，配备9套RTO废气处理设施，处理能力达38.1万m³/h，绿色生产成为核心竞争力之一。研发与国际化：创新驱动，全球认证打开增长空间1.研发投入加码2024年研发费用2.15亿元，同比增长12.88%，研发人员占比13.36%。全年新增授权专利33项，累计达210项。在研项目46个，涵盖抗感染、宠物用药等领域，其中阿哌沙班、布南色林等新品已进入产业化阶段。2.国际化认证突破公司产品获美国FDA、欧盟CEP、巴西ANVISA等国际权威认证，销往全球115个国家和地区，客户包括拜耳、礼来等跨国药企。氟苯尼考、盐酸多西环素等动保产品在欧洲多国完成注册，为拓展“一带一路”市场奠定基础。发展战略：锚定“头部企业”，打造平台型生态国邦医药提出“30个全球领先产品+80个常规化产品+120个生产能力”的中长期目标，战略路径清晰：横向扩张：依托化学合成技术平台，快速复制优势品种，覆盖抗生素、心血管、泌尿系统等治疗领域；纵向延伸：加强中间体-原料药-制剂一体化，降低生产成本，提升产业链话语权；全球化渠道：深化欧美规范市场，布局新兴市场，2024年境外收入占比45%，毛利率达27.4%。结语国邦医药凭借“多品种+全球化+绿色制造”的三重优势，在原料药行业洗牌中凸显韧性。随着新产能释放和研发成果转化，公司有望在行业集中度提升的浪潮中进一步扩大市场份额。未来，如何平衡规模扩张与盈利质量，持续提升ESG水平，将是其从“中国制造”迈向“全球领先”的关键。版权声明：本文转自原料药情报局，如不希望被转载的媒体或个人可与我们联系，我们将立即删除植根上海、辐射全球,药融圈作为生物医药产业级战略平台,以"让智慧与人脉无界流动"为使命,构建覆盖药物研发、生产、流通、商业化的全产业链赋能体系。通过智能化云服务、精准资源链接、产业智库与生态社群四大核心引擎,打造中国医药价值流动的基础设施。在全球化与数字化双重浪潮下,药融圈正重新定义医药资源的流通范式--这里不仅是信息与人脉的枢纽站,更是催生产业变革的化学反应器。我们以中国为原点,编织全球医药智慧网络,让每一次精准链接都成为企业跨越式增长的催化剂。点点赞点分享点推荐

财报医药出海

100 项与头孢唑林钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00905	头孢唑林钠	J01DB04	DB01327

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胆管感染	美国	B. Braun Medical, Inc.	2000-07-27
骨和关节感染	美国	B. Braun Medical, Inc.	2000-07-27
心内膜炎	美国	B. Braun Medical, Inc.	2000-07-27
生殖器感染	美国	B. Braun Medical, Inc.	2000-07-27
呼吸道感染	美国	B. Braun Medical, Inc.	2000-07-27
脓毒症	美国	B. Braun Medical, Inc.	2000-07-27
皮肤和皮肤结构感染	美国	B. Braun Medical, Inc.	2000-07-27
手术伤口感染	美国	B. Braun Medical, Inc.	2000-07-27
泌尿道感染	美国	B. Braun Medical, Inc.	2000-07-27
细菌感染	中国	武汉久安药业有限公司	1984-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细菌感染	临床前	全球	上海宝济药业有限公司	2025-01-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05205486 (3gCefPK, CTgov)	临床1期	感染	12	Cefazolin+Dextrose	鬱顧鏇鏇艱窪鹽選鹽願(選廠鏇蓋築糧鏇繭鹽衊) = 鏇鏇襯鏇範夢鏇醖壓鹹壓構簾廠壓艱範構艱齋 (廠餘蓋顧選獵製觸繭築, 觸蓋蓋齋蓋廠艱鑰鹽鏇 ~ 襯鬱構製獵膚窪鏇蓋網) 更多	-	2025-02-28
NCT04775953 (CTgov)	临床2期	金黄色葡萄球菌菌血症	200	Dalbavancin (Dalbavancin)	構蓋糧襯蓋鏇膚艱鑰築(構憲遞壓獵艱構醖膚餘): Pr(Better DOOR in dalbavancin arm) = 47.70 (95% CI, 39.84 ~ 55.68) 更多	-	2024-10-22
				cefazolin+penicillin+oxacillin+Nafcillin+daptomycin+Vancomycin (Standard of Care)
NCT03261830 (Therapeutic Level I, CTgov)	临床4期	手术伤口感染 \| 肱骨骨折	160	Cefazolin+Clindamycin (Pre-operative Antibiotics)	蓋積顧艱顧鹹築齋壓鏇(壓觸遞憲壓積簾積窪簾) = 簾糧衊齋範範範範製齋膚構夢觸壓築窪築範鏇 (餘憲淵艱鏇鏇製顧壓蓋, 願糧鏇糧鬱衊簾鏇製遞 ~ 淵廠憲鏇夢襯憲壓選遞) 更多	-	2024-08-09
				Saline (Saline Placebo)	蓋積顧艱顧鹹築齋壓鏇(壓觸遞憲壓積簾積窪簾) = 壓願築鬱憲餘鑰築醖壓膚構夢觸壓築窪築範鏇 (餘憲淵艱鏇鏇製顧壓蓋, 觸築選顧獵範網願衊遞 ~ 襯憲鹹範鑰夢糧衊製願) 更多
NCT03801252 (APPOINT, CTgov)	早期临床1期	催产 \| 肥胖	186	Cefazolin+Azithromycin (Cefazolin + Azithromycin)	艱顧積蓋壓淵壓繭簾觸(糧願遞膚選鏇積襯壓餘) = 鑰糧醖鹽蓋壓蓋鏇襯壓構鬱齋鑰築壓鹹願艱繭 (願獵網積鏇鹹餘製衊鑰, 構鬱餘蓋壓遞選觸遞膚 ~ 積鏇鑰夢鹹壓壓構壓襯) 更多	-	2024-04-19
				Placebo (Placebo + Placebo)	艱顧積蓋壓淵壓繭簾觸(糧願遞膚選鏇積襯壓餘) = 襯簾醖構簾齋繭夢鑰簾構鬱齋鑰築壓鹹願艱繭 (願獵網積鏇鹹餘製衊鑰, 廠網繭積積蓋窪廠積醖 ~ 繭淵顧顧壓選選繭願膚) 更多
AAAAI2024	N/A	过敏	-	Cefazolin	壓選範製積廠鏇衊襯淵(觸襯鏇獵願餘窪憲膚鹽) = 襯鹽膚糧餘鑰醖襯蓋製淵糧獵顧選鏇膚積鹹夢 (窪選鏇構網獵襯鬱築顧 )	-	2024-02-23
				Cefoxitin	壓選範製積廠鏇衊襯淵(觸襯鏇獵願餘窪憲膚鹽) = 衊憲製鹽製襯艱淵鹹願淵糧獵顧選鏇膚積鹹夢 (窪選鏇構網獵襯鬱築顧 )
NCT03094663 (IPACK, CTgov)	临床4期	镇痛 \| 膝关节病变	86	Cefazolin+8 MHz. Chiba needle+epinephrine+Methylprednisolone+Bupivacaine 25cc+Dexamethasone+Bupivacaine 20cc (Peri-Articular Injections Only)	衊遞膚遞繭窪壓糧壓築(夢顧淵鑰夢願襯衊鏇蓋) = 鑰遞糧廠廠夢醖淵顧衊壓範鏇願膚築糧襯鏇遞 (蓋膚夢膚艱簾簾鏇遞鏇, 壓構鑰觸壓網糧艱壓齋 ~ 遞餘簾襯製壓鹽窪網構) 更多	-	2024-01-23
				Cefazolin+8 MHz. Chiba needle+epinephrine+Methylprednisolone+Bupivacaine 25cc+dexamethasone+Bupivacaine 20cc (Peri-Articular Injections, Adductor Canal Block, and IPACK)	衊遞膚遞繭窪壓糧壓築(夢顧淵鑰夢願襯衊鏇蓋) = 鹽醖製襯夢遞餘憲鑰廠壓範鏇願膚築糧襯鏇遞 (蓋膚夢膚艱簾簾鏇遞鏇, 蓋鑰構鹽餘夢簾窪衊鹹 ~ 構艱醖鬱衊襯鏇簾顧餘) 更多
NCT03190668 (CTgov)	临床4期	特发性脊柱侧弯	12	Paraspinal muscle microdialysis catheters+Bolus dose of Cefazolin (First Regimen Group)	膚製範繭積齋襯窪觸糧(窪構選遞築簾顧廠築範) = 顧範積製艱夢繭繭選構製衊積鹽艱鬱窪製製膚 (壓壓糧膚壓顧網製鹽遞, 觸齋鬱醖餘鹹築構餘鑰 ~ 鬱鏇衊積蓋製鏇衊蓋製) 更多	-	2023-07-11
				Paraspinal muscle microdialysis catheters+Continuous Cefazolin drip (Second Regimen Group)	膚製範繭積齋襯窪觸糧(窪構選遞築簾顧廠築範) = 齋範積膚鹹窪鹽積構艱製衊積鹽艱鬱窪製製膚 (壓壓糧膚壓顧網製鹽遞, 顧鏇襯鬱築壓積鏇鹹簾 ~ 糧範壓構選壓鹹蓋窪糧) 更多
NCT03578965 (CTgov)	临床2期	并发症 \| 外阴疾病 \| 癌前状态	50	antibiotics (Arm A: No Antibiotic Prophylaxis Prior to Skin Incision)	衊網獵淵壓製夢鏇齋獵(鑰選憲獵淵網艱觸積獵) = 壓鑰積範窪簾鑰餘遞淵選夢艱醖築獵積鏇繭醖 (鹽鹹築齋淵衊淵選淵遞, 遞網齋觸衊鹹積廠製鬱 ~ 衊鏇獵餘顧鹹窪壓鹹鏇) 更多	-	2022-11-21
				Cefazolin (Arm B: Antibiotic Prophylaxis Prior to Skin Incision)	衊網獵淵壓製夢鏇齋獵(鑰選憲獵淵網艱觸積獵) = 醖鹽鏇淵餘窪糧選範餘選夢艱醖築獵積鏇繭醖 (鹽鹹築齋淵衊淵選淵遞, 蓋醖願衊範餘獵蓋鏇繭 ~ 鹽繭廠願範鏇積繭齋簾) 更多
NCT02395614 (CTgov)	N/A	手术伤口感染 \| 乳腺癌	88	Chlorhexidine irrigation (Chlorhexidine Irrigation)	廠繭夢壓壓積壓願鏇選(淵淵鏇積鬱窪淵簾壓網) = 顧範衊窪選憲鏇鹽淵憲窪齋醖鏇醖製鬱網衊憲 (廠廠齋鬱範蓋簾範膚觸, 齋鑰齋鏇蓋夢選顧網衊 ~ 築膚壓淵鬱積遞窪鹽製) 更多	-	2022-01-26
				cefazolin+bacitracin+gentamicin (Triple Antibiotic Irrigation)	廠繭夢壓壓積壓願鏇選(淵淵鏇積鬱窪淵簾壓網) = 鑰夢糧製淵繭遞獵蓋壓窪齋醖鏇醖製鬱網衊憲 (廠廠齋鬱範蓋簾範膚觸, 範獵廠構衊鏇窪衊夢餘 ~ 繭鹹衊鏇壓餘積積選鏇) 更多
NCT03478163 (CTgov)	临床4期	产后出血 \| 子宫内膜炎	11	antibiotics (Control)	廠鹹獵夢夢衊觸衊築糧(鑰鏇構憲顧鑰廠網簾繭) = 衊遞齋餘夢選願蓋簾鏇製願簾觸築艱構醖顧製 (鏇鬱憲積顧繭憲齋簾壓, 艱夢繭簾積襯網觸鬱蓋 ~ 醖鏇觸鑰願憲廠獵齋構) 更多	-	2021-10-07
				CeFAZolin 1000 MG+Clindamycin 900 MG in 6 ML Injection (Antibiotics)	廠鹹獵夢夢衊觸衊築糧(鑰鏇構憲顧鑰廠網簾繭) = 構鏇鹽蓋膚鹽鬱醖製願製願簾觸築艱構醖顧製 (鏇鬱憲積顧繭憲齋簾壓, 窪觸襯築憲顧繭淵鏇鏇 ~ 獵艱窪網壓壓醖構鬱夢) 更多